Suzhou Ribo Life Science Launches Hong Kong IPO to Raise HK$1.6 Billion

MT Newswires Live2025-12-31

Suzhou Ribo Life Science (HKG:6938) launched its Hong Kong initial public offering on Wednesday, aiming to raise HK$1.59 billion.

The life sciences company is offering 27,487,400 H shares at an indicative price of HK$57.97 per share, according to a Wednesday Hong Kong bourse filing.

The offering comprises 2.7 million H shares for Hong Kong investors and 24.7 million H shares for international investors, subject to reallocation and the overallotment option.

The company secured 11 cornerstone investors, who committed to subscribing to $100 million worth of IPO shares.

The issuer expects to disclose the allocations on Jan. 8 and start trading on the Hong Kong bourse on Jan. 9.

Net proceeds will primarily be used for the research and development of the company's core product RBD4059, as well as RBD5044 and RBD1016. Funds will also be used to fund the research and development of the company's preclinical assets.

China International Capital Corporation Hong Kong, Citigroup Global Markets Asia, ICBC International Securities, BOCI Asia, Macquarie Capital, ABCI Securities, SDIC Securities (Hong Kong), and Futu Securities International (Hong Kong) are the joint bookrunners of the IPO.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2595741179?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-31 09:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595741179","market":"us","top_or_hot":-1,"title":"Suzhou Ribo Life Science Launches Hong Kong IPO to Raise HK$1.6 Billion","media":"MT Newswires Live","content":"<html><body><p> Suzhou Ribo Life Science (HKG:6938) launched its Hong Kong initial public offering on Wednesday, aiming to raise HK$1.59 billion.</p><p>The life sciences company is offering 27,487,400 H shares at an indicative price of HK$57.97 per share, according to a Wednesday Hong Kong bourse filing.</p><p>The offering comprises 2.7 million H shares for Hong Kong investors and 24.7 million H shares for international investors, subject to reallocation and the overallotment option.</p><p>The company secured 11 cornerstone investors, who committed to subscribing to $100 million worth of IPO shares.</p><p>The issuer expects to disclose the allocations on Jan. 8 and start trading on the Hong Kong bourse on Jan. 9.</p><p>Net proceeds will primarily be used for the research and development of the company's core product RBD4059, as well as RBD5044 and RBD1016. Funds will also be used to fund the research and development of the company's preclinical assets.</p><p>China International Capital Corporation Hong Kong, Citigroup Global Markets Asia, ICBC International Securities, BOCI Asia, <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a> Capital, ABCI Securities, SDIC Securities (Hong Kong), and Futu Securities International (Hong Kong) are the joint bookrunners of the IPO.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Suzhou Ribo Life Science Launches Hong Kong IPO to Raise HK$1.6 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSuzhou Ribo Life Science Launches Hong Kong IPO to Raise HK$1.6 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-31 09:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Suzhou Ribo Life Science (HKG:6938) launched its Hong Kong initial public offering on Wednesday, aiming to raise HK$1.59 billion.</p><p>The life sciences company is offering 27,487,400 H shares at an indicative price of HK$57.97 per share, according to a Wednesday Hong Kong bourse filing.</p><p>The offering comprises 2.7 million H shares for Hong Kong investors and 24.7 million H shares for international investors, subject to reallocation and the overallotment option.</p><p>The company secured 11 cornerstone investors, who committed to subscribing to $100 million worth of IPO shares.</p><p>The issuer expects to disclose the allocations on Jan. 8 and start trading on the Hong Kong bourse on Jan. 9.</p><p>Net proceeds will primarily be used for the research and development of the company's core product RBD4059, as well as RBD5044 and RBD1016. Funds will also be used to fund the research and development of the company's preclinical assets.</p><p>China International Capital Corporation Hong Kong, Citigroup Global Markets Asia, ICBC International Securities, BOCI Asia, <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a> Capital, ABCI Securities, SDIC Securities (Hong Kong), and Futu Securities International (Hong Kong) are the joint bookrunners of the IPO.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06938","symbol_name":"瑞博生物-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2595741179","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595741179","pubTimestamp":1767145193,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Suzhou Ribo Life Science  launched its Hong Kong initial public offering on Wednesday, aiming to raise HK$1.59 billion.The life sciences company is offering 27,487,400 H shares at an indicative price of HK$57.97 per share, according to a Wednesday Hong Kong bourse filing.The offering comprises 2.7 million H shares for Hong Kong investors and 24.7 million H shares for international investors, subject to reallocation and the overallotment option.The company secured 11 cornerstone investors, who committed to subscribing to $100 million worth of IPO shares.The issuer expects to disclose the allocations on Jan. 8 and start trading on the Hong Kong bourse on Jan. 9.Net proceeds will primarily be used for the research and development of the company's core product RBD4059, as well as RBD5044 and RBD1016. Funds will also be used to fund the research and development of the company's preclinical assets.China International Capital Corporation Hong Kong, Citigroup Global Markets Asia, ICBC Internat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06938":"瑞博生物-B"},"translate_title":"苏州日博生命科学启动香港IPO募资16亿港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":0.9},"content_text":"Suzhou Ribo Life Science (HKG:6938) launched its Hong Kong initial public offering on Wednesday, aiming to raise HK$1.59 billion.The life sciences company is offering 27,487,400 H shares at an indicative price of HK$57.97 per share, according to a Wednesday Hong Kong bourse filing.The offering comprises 2.7 million H shares for Hong Kong investors and 24.7 million H shares for international investors, subject to reallocation and the overallotment option.The company secured 11 cornerstone investors, who committed to subscribing to $100 million worth of IPO shares.The issuer expects to disclose the allocations on Jan. 8 and start trading on the Hong Kong bourse on Jan. 9.Net proceeds will primarily be used for the research and development of the company's core product RBD4059, as well as RBD5044 and RBD1016. Funds will also be used to fund the research and development of the company's preclinical assets.China International Capital Corporation Hong Kong, Citigroup Global Markets Asia, ICBC International Securities, BOCI Asia, Macquarie Capital, ABCI Securities, SDIC Securities (Hong Kong), and Futu Securities International (Hong Kong) are the joint bookrunners of the IPO.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595741179","isCrawlerRequest":true}